Search

Your search keyword '"Kupcinskas, L"' showing total 366 results
Start Over Author "Kupcinskas, L"
366 results on '"Kupcinskas, L"'

51. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report

Author

Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E. M., Agreus, L., Andersen, L. P., Axon, A., Coelho, L., Delchier, J. C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K. M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K. L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J. C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., You, W., Gastroenterology & Hepatology, Malfertheiner, P., Megraud, F., O'Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D.Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E.M., Agreus, L., Andersen, L.P., Axon, A., Coelho, L., Delchier, J.C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K.M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K.L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J.C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., and You, W.

Subjects
Helicobacter pylori infection, Proton Pump Inhibitor, Gastroenterology, 0302 clinical medicine, Fluoroquinolone, Risk Factors, HELICOBACTER THERAPY, Medicine, Early Detection of Cancer, Evidence-Based Medicine, biology, Microbial Sensitivity Test, Stomach, Consensus conference, Anti-Bacterial Agents, Nitroimidazoles, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Fluoroquinolones, Human, medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, Microbial Sensitivity Tests, Helicobacter Infections, 03 medical and health sciences, Stomach Neoplasms, Stomach Neoplasm, Internal medicine, Clarithromycin, Clarithromycin resistance, Anti-Bacterial Agent, Drug Resistance, Bacterial, Gastroscopy, Humans, Dyspepsia, GASTRITIS, HELICOBACTER PYLORI, Helicobacter pylori, business.industry, Public health, Nitroimidazole, Risk Factor, Gastriti, Amoxicillin, Proton Pump Inhibitors, biology.organism_classification, Gastrointestinal Microbiome, Family medicine, business, Bismuth, Helicobacter Infection
Abstract

Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. Pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/ Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.

Published
2017

53. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Author

Momozawa, Y., Dmitrieva, J., Theatre, E., Deffontaine, V., Rahmouni, S., Charloteaux, B., Crins, F., Docampo, E., Elansary, M., Gori, A.S., Lecut, C., Mariman, R., Mni, M., Oury, C., Altukhov, I., Alexeev, D., Aulchenko, Y., Amininejad, L., Bouma, G., Hoentjen, F., Lowenberg, M., Oldenburg, B., Pierik, M.J., vander Meulen-de Jong, A.E., Woude, C.J. van der, Visschedijk, M.C., Lathrop, M., Hugot, J.P., Weersma, R.K., Vos, M. de, Franchimont, D., Vermeire, S., Kubo, M., Louis, E., Georges, M., Abraham, C., Achkar, J.P., Ahmad, T., Ananthakrishnan, A.N., Andersen, V., Anderson, C.A., Andrews, J.M., Annese, V., Aumais, G., Baidoo, L., Baldassano, R.N., Bampton, P.A., Barclay, M., Barrett, J.C., Bayless, T.M., Bethge, J., Bitton, A., Boucher, G., Brand, S., Brandt, B., Brant, S.R., Buning, C., Chew, A., Cho, J.H., Cleynen, I., Cohain, A., Croft, A., Daly, M.J., D'Amato, M., Danese, S., Jong, D. de, Denapiene, G., Denson, L.A., Devaney, K.L., Dewit, O., D'Inca, R., Dubinsky, M., Duerr, R.H., Edwards, C., Ellinghaus, D., Essers, J., Ferguson, L.R., Festen, E.A., Fleshner, P., Florin, T., Franke, A., Fransen, K., Gearry, R., Gieger, C., Glas, J., Goyette, P., Green, T., Griffiths, A.M., Guthery, S.L., Hakonarson, H., Halfvarson, J., Hanigan, K., Haritunians, T., Hart, A., Hawkey, C., Hayward, N.K., Hedl, M., Henderson, P., Hu, X.H., Huang, H.L., Hui, K.Y., Imielinski, M., Ippoliti, A., Jonaitis, L., Jostins, L., Karlsen, T.H., Kennedy, N.A., Khan, M.A., Kiudelis, G., Krishnaprasad, K., Kugathasan, S., Kupcinskas, L., Latiano, A., Laukens, D., Lawrance, I.C., Lee, J.C., Lees, C.W., Leja, M., Limbergen, J. van, Lionetti, P., Liu, J.Z., Mahy, G., Mansfield, J., Massey, D., Mathew, C.G., McGovern, D.P.B., Milgrom, R., Mitrovic, M., Montgomery, G.W., Mowat, C., Newman, W., Ng, A., Ng, S.C., Ng, S.M.E., Nikolaus, S., Ning, K., Nothen, M., Oikonomou, I., Palmieri, O., Parkes, M., Phillips, A., Ponsioen, C.Y., Potocnik, U., Prescott, N.J., Proctor, D.D., Radford-Smith, G., Rahier, J.F., Raychaudhuri, S., Regueiro, M., Rieder, F., Rioux, J.D., Ripke, S., Roberts, R., Russell, R.K., Sanderson, J.D., Sans, M., Satsangi, J., Schadt, E.E., Schreiber, S., Schulte, D., Schumm, L.P., Scott, R., Seielstad, M., Sharma, Y., Silverberg, M.S., Simms, L.A., Skieceviciene, J., Spain, S.L., Steinhart, A.H., Stempak, J.M., Stronati, L., Sventoraityte, J., Targan, S.R., Taylor, K.M., Velde, A. ter, Torkvist, L., Tremelling, M., Sommeren, S. van, Vasiliauskas, E., Verspaget, H.W., Walters, T., Wang, K., Wang, M.H., Wei, Z., Whiteman, D., Wijmenga, C., Wilson, D.C., Winkelmann, J., Xavier, R.J., Zhang, B., Zhang, C.K., Zhang, H., Zhang, W., Zhao, H.Y., Zhao, Z.Z., and Int IBD Genetics Consortium

Published
2018

54. Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort

Author

Burisch, J., Andersen, V., Cukovic-Cavka, S., Lakatos, P. L., D Inca, R., Magro, F., Arebi, N., Kievit, L., Kaimakliotis, I., Valpiani, D., Katsanos, K. H., Vegh, Z., Dahlerup, J. F., Fumery, M., Pedersen, N., Halfvarson, J., Belousova, E., Nielsen, K. R., Turcan, S., Ellul, P., Kupcinskas, L., Oksanen, P., Duricova, D., Giannotta, M., Goldis, A., Vicent Hernandez, Salupere, R., Odes, S., Langholz, E., and Munkholm, P.

Subjects
616.344-002-031.84 [udc], Crohn disease, diagnosis, therapy, Biological therapy, methods, Immunologic factors, therapeutic use, Cohort studies, Regression analysis, Europe
Abstract

Background: Immunomodulators have both been shown to improve the disease course in IBD patients: however, the literature remains inconsistent. The aim of the study was to investigate the impact of treatment with immunomodulators and biological therapy on disease course and prognosis of patients diagnosed with Crohn’s disease (CD) from diagnosis and during the first 5 years of follow-up. Methods: The Epi-IBD cohort is a prospective population-based cohort of 1289 unselected, uniformly diagnosed patients with IBD diagnosed in 2010 in centres from Western and Eastern European countries. Clinical data were captured prospectively throughout the follow-up period. Associations between primary endpoints (surgery and hospitalisation) and covariates were analysed by stepwise Cox regression analysis using the proportional hazards assumption. The use of immunomodulators and biologics were included as time-dependent variables with an initial lag time of 3 months and 2 months, respectively. Results: A total of 488 (38%) patients were diagnosed with CD and included in the study. Patient characteristics are shown in Table 1. Prevalence of treatments on any given day during follow-up is shown in Figure 1. In total, 107 CD patients (22%) had a resection, while 176 (36%) patients were hospitalised because of CD. Treatment with immunomodulators was associated with a reduced risk of surgery (HR: 0.4 CI95% 0.2–0.6) as well as needing hospitalisation (HR: 0.3 CI95% 0.2–0.5) (Figure 2), while biological therapy was not (HR: 0.8 (0.4–1.3) and HR: 0.7 (0.5–1.2)). Other factors included in the regression analusis are shown in Table 2 [...].

Published
2018

55. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Author

Momozawa, Y. (Yukihide), Dmitrieva, J. (Julia), Théâtre, E. (Emilie), Deffontaine, V. (Valérie), Rahmouni, S. (Souad), Charloteaux, B. (Benoît), Crins, F. (François), Docampo, E. (Elisa), Elansary, M. (Mahmoud), Gori, A.-S. (Ann-Stephan), Lecut, C. (Christelle), Mariman, R. (Rob), Mni, M. (Myriam), Oury, C. (Cécile), Altukhov, I. (Ilya), Alexeev, D. (Dmitry), Aulchenko, Y.S. (Yurii), Amininejad, L. (Leila), Bouma, G. (Gerd), Hoentjen, F., Löwenberg, M., Oldenburg, B. (Bas), Pierik, M. (Marieke), Vander Meulen-De Jong, A.E. (Andrea E.), Woude, C.J. (Janneke) van der, Visschedijk, M. (Marijn), Lathrop, M. (Mark), Hugot, J.P. (J.), Weersma, R.K. (Rinse), De Vos, M. (Martine), Franchimont, D. (Denis), Vermeire, S. (Séverine), Kubo, M. (Michiaki), Louis, E. (Edouard), Georges, M. (Michel), Abraham, C. (Clara), Achkar, J.-P. (Jean-Paul), Ahmad, T. (Tariq), Ananthakrishnan, A.N. (Ashwin N.), Andersen, V. (Vibeke), Anderson, C.A. (Carl A.), Andrews, J.M. (Jane M.), Annese, V. (Vito), Aumais, G. (Guy), Baidoo, L. (Leonard), Baldassano, R.N. (Robert), Bampton, P.A. (Peter A.), Barclay, M. (Murray), Barrett, J.C. (Jeffrey), Bayless, T.M. (Theodore M.), Bethge, J. (Johannes), Bitton, A., Boucher, G. (Gabrielle), Brand, S. (Stephan), Brandt, B. (Berenice), Brant, S.R. (Steven R.), Büning, C. (Carsten), Chew, A. (Angela), Cho, J.H. (Judy H.), Cleynen, I. (Isabelle), Cohain, A. (Ariella), Croft, A. (Anthony), Daly, M.J. (Mark J.), D'Amato, M. (Mauro), Danese, S. (Silvio), De Jong, D.J. (Dirk J.), Denapiene, G. (Goda), Denson, L.A. (Lee A.), Devaney, K.L. (Kathy L.), Dewit, O. (Olivier), D'Inca, R. (Renata), Dubinsky, M. (Marla), Duerr, R.H. (Richard), Edwards, C. (Cathryn), Ellinghaus, D. (David), Essers, J.B. (Jonah), Ferguson, L.R. (Lynnette R.), Festen, E.A.M. (Eleonora), Fleshner, P. (Philip), Florin, T. (Tim), Franke, A. (Andre), Fransen, K. (Karin), Gearry, R. (Richard), Gieger, C. (Christian), Glas, J. (Jürgen), Goyette, P. (Philippe), Green, T. (Todd), Griffiths, A.M. (Anne), Guthery, S.L. (Stephen L.), Hakonarson, H. (Hakon), Halfvarson, J. (Jonas), Hanigan, K. (Katherine), Haritunians, T. (Talin), Hart, A. (Ailsa), Hawkey, S., Hayward, N.K. (Nicholas K.), Hedl, M. (Matija), Henderson, P. (Paul), Hu, X. (Xinli), Huang, H. (Hailiang), Hui, K.Y. (Ken Y.), Imielinski, M. (Marcin), Ippoliti, A. (Andrew), Jonaitis, L. (Laimas), Jostins, L. (Luke), Karlsen, T.H. (Tom), Kennedy, N.A. (Nicholas A.), Khan, M.A. (Mohammed Azam), Kiudelis, G. (Gediminas), Krishnaprasad, K. (Krupa), Kugathasan, S. (Subra), Kupcinskas, L. (Limas), Latiano, A. (Anna), Laukens, D. (Debby), Lawrance, I.C. (Ian C.), Lee, J.C. (James C.), Lees, C.W. (Charlie), Leja, M. (Marcis), Van Limbergen, J. (Johan), Lionetti, P. (Paolo), Liu, J.Z. (Jimmy Z.), Mahy, G. (Gillian), Mansfield, J. (John), Massey, D. (Dunecan), Mathew, J. (Joseph), McGovern, D.P.B. (Dermot P.B.), Milgrom, R. (Raquel), Mitrovic, M. (Mitja), Montgomery, G.W. (Grant W.), Mowat, C. (Craig), Newman, W.G. (William G.), Ng, A. (Aylwin), Ng, S.C. (Siew C.), Ng, S.M.E. (Sok Meng Evelyn), Nikolaus, S. (Susanna), Ning, K. (Kaida), Nöthen, M.M. (Markus), Oikonomou, I. (Ioannis), Palmieri, O. (Orazio), Parkes, M. (Miles), Phillips, A. (Anne), Ponsioen, C.Y. (Cyril), Potocnik, U. (Uros), Prescott, N.J. (Natalie J.), Proctor, D.D. (Deborah D.), Radford-Smith, G. (Graham), Rahier, J.F. (J.), Raychaudhuri, S. (Soumya), Regueiro, M. (Miguel), Rieder, F. (Florian), Rioux, J.D. (John), Ripke, S. (Stephan), Roberts, R. (Rebecca), Russell, R.K. (Richard), Sanderson, J.D. (Jeremy), Sans, S. (Susana), Satsangi, J. (Jack), Schadt, E.E. (Eric), Schreiber, S. (Stefan), Schulte, D. (Dominik), Schumm, L.P. (L. Philip), Scott, R. (Regan), Seielstad, M. (Mark), Sharma, Y. (Yashoda), Silverberg, M. (Mark), Simms, L.A. (Lisa A.), Skieceviciene, J. (Jurgita), Spain, S.L. (Sarah L.), Steinhart, A.H. (A. Hillary), Stempak, J.M. (Joanne M.), Stronati, L. (Laura), Sventoraityte, J. (Jurgita), Targan, S.R. (Stephan R.), Taylor, K.M. (Kirstin M.), Ter Velde, A. (Anje), Torkvist, L. (Leif), Tremelling, M. (Mark), Van Sommeren, S. (Suzanne), Vasiliauskas, E. (Eric), Verspaget, H.W., Walters, T. (Thomas), Wang, K. (Kai), Wang, M.-H. (Ming-Hsi), Wei, Z. (Zhi), Whiteman, D.C. (David C.), Wijmenga, C. (Cisca), Wilson, D.C. (David C.), Winkelmann, B., Xavier, R.J. (Ramnik J.), Zhang, B. (Bin), Zhang, C.K. (Clarence K.), Zhang, H. (Hu), Zhang, W. (Wei), Zhao, H. (Hongyu), Zhao, Z.Z. (Zhen Z.), Momozawa, Y. (Yukihide), Dmitrieva, J. (Julia), Théâtre, E. (Emilie), Deffontaine, V. (Valérie), Rahmouni, S. (Souad), Charloteaux, B. (Benoît), Crins, F. (François), Docampo, E. (Elisa), Elansary, M. (Mahmoud), Gori, A.-S. (Ann-Stephan), Lecut, C. (Christelle), Mariman, R. (Rob), Mni, M. (Myriam), Oury, C. (Cécile), Altukhov, I. (Ilya), Alexeev, D. (Dmitry), Aulchenko, Y.S. (Yurii), Amininejad, L. (Leila), Bouma, G. (Gerd), Hoentjen, F., Löwenberg, M., Oldenburg, B. (Bas), Pierik, M. (Marieke), Vander Meulen-De Jong, A.E. (Andrea E.), Woude, C.J. (Janneke) van der, Visschedijk, M. (Marijn), Lathrop, M. (Mark), Hugot, J.P. (J.), Weersma, R.K. (Rinse), De Vos, M. (Martine), Franchimont, D. (Denis), Vermeire, S. (Séverine), Kubo, M. (Michiaki), Louis, E. (Edouard), Georges, M. (Michel), Abraham, C. (Clara), Achkar, J.-P. (Jean-Paul), Ahmad, T. (Tariq), Ananthakrishnan, A.N. (Ashwin N.), Andersen, V. (Vibeke), Anderson, C.A. (Carl A.), Andrews, J.M. (Jane M.), Annese, V. (Vito), Aumais, G. (Guy), Baidoo, L. (Leonard), Baldassano, R.N. (Robert), Bampton, P.A. (Peter A.), Barclay, M. (Murray), Barrett, J.C. (Jeffrey), Bayless, T.M. (Theodore M.), Bethge, J. (Johannes), Bitton, A., Boucher, G. (Gabrielle), Brand, S. (Stephan), Brandt, B. (Berenice), Brant, S.R. (Steven R.), Büning, C. (Carsten), Chew, A. (Angela), Cho, J.H. (Judy H.), Cleynen, I. (Isabelle), Cohain, A. (Ariella), Croft, A. (Anthony), Daly, M.J. (Mark J.), D'Amato, M. (Mauro), Danese, S. (Silvio), De Jong, D.J. (Dirk J.), Denapiene, G. (Goda), Denson, L.A. (Lee A.), Devaney, K.L. (Kathy L.), Dewit, O. (Olivier), D'Inca, R. (Renata), Dubinsky, M. (Marla), Duerr, R.H. (Richard), Edwards, C. (Cathryn), Ellinghaus, D. (David), Essers, J.B. (Jonah), Ferguson, L.R. (Lynnette R.), Festen, E.A.M. (Eleonora), Fleshner, P. (Philip), Florin, T. (Tim), Franke, A. (Andre), Fransen, K. (Karin), Gearry, R. (Richard), Gieger, C. (Christian), Glas, J. (Jürgen), Goyette, P. (Philippe), Green, T. (Todd), Griffiths, A.M. (Anne), Guthery, S.L. (Stephen L.), Hakonarson, H. (Hakon), Halfvarson, J. (Jonas), Hanigan, K. (Katherine), Haritunians, T. (Talin), Hart, A. (Ailsa), Hawkey, S., Hayward, N.K. (Nicholas K.), Hedl, M. (Matija), Henderson, P. (Paul), Hu, X. (Xinli), Huang, H. (Hailiang), Hui, K.Y. (Ken Y.), Imielinski, M. (Marcin), Ippoliti, A. (Andrew), Jonaitis, L. (Laimas), Jostins, L. (Luke), Karlsen, T.H. (Tom), Kennedy, N.A. (Nicholas A.), Khan, M.A. (Mohammed Azam), Kiudelis, G. (Gediminas), Krishnaprasad, K. (Krupa), Kugathasan, S. (Subra), Kupcinskas, L. (Limas), Latiano, A. (Anna), Laukens, D. (Debby), Lawrance, I.C. (Ian C.), Lee, J.C. (James C.), Lees, C.W. (Charlie), Leja, M. (Marcis), Van Limbergen, J. (Johan), Lionetti, P. (Paolo), Liu, J.Z. (Jimmy Z.), Mahy, G. (Gillian), Mansfield, J. (John), Massey, D. (Dunecan), Mathew, J. (Joseph), McGovern, D.P.B. (Dermot P.B.), Milgrom, R. (Raquel), Mitrovic, M. (Mitja), Montgomery, G.W. (Grant W.), Mowat, C. (Craig), Newman, W.G. (William G.), Ng, A. (Aylwin), Ng, S.C. (Siew C.), Ng, S.M.E. (Sok Meng Evelyn), Nikolaus, S. (Susanna), Ning, K. (Kaida), Nöthen, M.M. (Markus), Oikonomou, I. (Ioannis), Palmieri, O. (Orazio), Parkes, M. (Miles), Phillips, A. (Anne), Ponsioen, C.Y. (Cyril), Potocnik, U. (Uros), Prescott, N.J. (Natalie J.), Proctor, D.D. (Deborah D.), Radford-Smith, G. (Graham), Rahier, J.F. (J.), Raychaudhuri, S. (Soumya), Regueiro, M. (Miguel), Rieder, F. (Florian), Rioux, J.D. (John), Ripke, S. (Stephan), Roberts, R. (Rebecca), Russell, R.K. (Richard), Sanderson, J.D. (Jeremy), Sans, S. (Susana), Satsangi, J. (Jack), Schadt, E.E. (Eric), Schreiber, S. (Stefan), Schulte, D. (Dominik), Schumm, L.P. (L. Philip), Scott, R. (Regan), Seielstad, M. (Mark), Sharma, Y. (Yashoda), Silverberg, M. (Mark), Simms, L.A. (Lisa A.), Skieceviciene, J. (Jurgita), Spain, S.L. (Sarah L.), Steinhart, A.H. (A. Hillary), Stempak, J.M. (Joanne M.), Stronati, L. (Laura), Sventoraityte, J. (Jurgita), Targan, S.R. (Stephan R.), Taylor, K.M. (Kirstin M.), Ter Velde, A. (Anje), Torkvist, L. (Leif), Tremelling, M. (Mark), Van Sommeren, S. (Suzanne), Vasiliauskas, E. (Eric), Verspaget, H.W., Walters, T. (Thomas), Wang, K. (Kai), Wang, M.-H. (Ming-Hsi), Wei, Z. (Zhi), Whiteman, D.C. (David C.), Wijmenga, C. (Cisca), Wilson, D.C. (David C.), Winkelmann, B., Xavier, R.J. (Ramnik J.), Zhang, B. (Bin), Zhang, C.K. (Clarence K.), Zhang, H. (Hu), Zhang, W. (Wei), Zhao, H. (Hongyu), and Zhao, Z.Z. (Zhen Z.)

Abstract

GWAS have identified >200 risk loci for Inflammatory Bowel Disease (IBD). The majority of disease associations are known to be driven by regulatory variants. To identify the putative causative genes that are perturbed by these variants, we generate a large transcriptome data set (nine disease-relevant cell types) and identify 23,650 cis-eQTL. We show that these are determined by ∼9720 regulatory modules, of which ∼3000 operate in multiple tissues and ∼970 on multiple genes. We identify regulatory modules that drive the disease association for 63 of the 200 risk loci, and show that these are enriched in multigenic modules. Based on these analyses, we resequence 45 of the corresponding 100 candidate genes in 6600 Crohn disease (CD) cases and 5500 controls, and show with burden tests that they include likely causative genes. Our analyses indicate that ≥10-fold larger sample sizes will be required to demonstrate the causality of individual genes using this approach.

Published
2018
Full Text
View/download PDF

56. Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort-the Epi-IBD cohort

Author

Burisch, J., Ellul, P., Arebi, N., Kaimakliotis, I., D'Inca, R., Andersen, V., Belousova, E., Hernandez, V., Vegh, Z., Turcan, S., Magro, F., Kupcinskas, L., Halfvarson, Jonas, Lakatos, P. L., Duricova, D., Kievit, L., Goldis, A., Dahlerup, J. F., Oksanen, P., Cukovic-Cavka, S., Fumery, M., Odes, S., Nielsen, K. R., Valpiani, D., Pedersen, N., Giannotta, M., Salupere, R., Katsanos, K. H., Langholz, E., Munkholm, P., Burisch, J., Ellul, P., Arebi, N., Kaimakliotis, I., D'Inca, R., Andersen, V., Belousova, E., Hernandez, V., Vegh, Z., Turcan, S., Magro, F., Kupcinskas, L., Halfvarson, Jonas, Lakatos, P. L., Duricova, D., Kievit, L., Goldis, A., Dahlerup, J. F., Oksanen, P., Cukovic-Cavka, S., Fumery, M., Odes, S., Nielsen, K. R., Valpiani, D., Pedersen, N., Giannotta, M., Salupere, R., Katsanos, K. H., Langholz, E., and Munkholm, P.

Published
2018

57. Prädisponierende Genvarianten bei Divertikulose und Divertikulitis

Author

Reichert, MC, additional, Kupcinskas, J, additional, Krawczyk, M, additional, Jüngst, C, additional, Casper, M, additional, Grünhage, F, additional, Appenrodt, B, additional, Zimmer, V, additional, Weber, S, additional, Tamelis, A, additional, Lukosiene, JI, additional, Pauziene, N, additional, Kiudelis, G, additional, Laimas, J, additional, Schramm, C, additional, Göser, T, additional, Schulz, A, additional, Malinowski, M, additional, Glanemann, M, additional, Kupcinskas, L, additional, and Lammert, F, additional

Published
2018
Full Text
View/download PDF

58. Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

Author

Hirschfield, G., primary, Kupcinskas, L., additional, Ott, P., additional, Beuers, U., additional, Bergquist, A.M., additional, Färkkilä, M., additional, Manns, M.P., additional, Pares, A., additional, Spengler, U., additional, Greinwald, R., additional, Proels, M., additional, and Poupon, R., additional

Published
2018
Full Text
View/download PDF

60. Disease course during the first five years following diagnosis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

61. Change in Crohn's disease behavior in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

62. The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

63. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

Author

Stange, E F, Travis, S P L, Vermeire, S, Beglinger, C, Kupcinskas, L, Geboes, K, Barakauskiene, A, Villanacci, V, Von Herbay, A, Warren, B F, Gasche, C, Tilg, H, Schreiber, Stefan W, Schölmerich, J, and Reinisch, W

Subjects
Europe, Evidence-Based Medicine, Crohn Disease, Clinical Laboratory Techniques, Recurrence, Biopsy, Drug Resistance, Gastroenterology, Humans, Medical History Taking, Physical Examination, Article, Endoscopy, Gastrointestinal
Published
2016

64. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes:a genetic association study

Author

Cleynen, Isabelle, Boucher, Gabrielle, Jostins, Luke, Schumm, L. Philip, Zeissig, Sebastian, Ahmad, Tariq, Andersen, Vibeke, Andrews, Jane M., Annese, Vito, Brand, Stephan, Brant, Steven R., Cho, Judy H., Daly, Mark J., Dubinsky, Marla, Duerr, Richard H., Ferguson, Lynnette R., Franke, Andre, Gearry, Richard B., Goyette, Philippe, Hakonarson, Hakon, Halfvarson, Jonas, Hov, Johannes R., Huang, Hailang, Kennedy, Nicholas A., Kupcinskas, Limas, Lawrance, Ian C., Lee, James C., Satsangi, Jack, Schreiber, Stephan, Théâtre, Emilie, Van Der Meulen De Jong, Andrea E, Weersma, Rinse K., Wilson, David C., Parkes, Miles, Vermeire, Severine, Rioux, John D., Mansfield, John, Silverberg, Mark S., Radford Smith, Graham, Mcgovern, Dermot P. B., Barrett, Jeffrey C., Lees, Charlie W, Abraham, C, Achkar, Jp, Ahmad, T, Amininejad, L, Ananthakrishnan, An, Andersen, V, Anderson, Ca, Andrews, Jm, Annese, V, Aumais, G, Baidoo, L, Baldassano, Rn, Bampton, Pa, Barclay, M, Barrett, Jc, Bayless, Tm, Bethge, J, Bis, Jc, Bitton, A, Boucher, G, Brand, S, Brandt, B, Brant, Sr, Büning, C, Chew, A, Cho, Jh, Cleynen, I, Cohain, A, Croft, A, Daly, Mj, D'Amato, M, Danese, S, De Jong, D, De Vos, M, Denapiene, G, Denson, La, Devaney, K, Dewit, O, D'Inca, R, Dubinsky, M, Duerr, Rh, Edwards, C, Ellinghaus, D, Essers, J, Ferguson, Lr, Festen, Ea, Fleshner, P, Florin, T, Franchimont, D, Franke, A, Fransen, K, Gearry, R, Georges, M, Gieger, C, Glas, J, Goyette, P, Green, T, Griffiths, Am, Guthery, Sl, Hakonarson, H, Halfvarson, J, Hanigan, K, Haritunians, T, Hart, A, Hawkey, C, Hayward, Nk, Hedl, M, Henderson, P, Hu, X, Huang, H, Hui, Ky, Imielinski, M, Ippoliti, A, Jonaitis, L, Jostins, L, Karlsen, Th, Kennedy, Na, Khan, Ma, Kiudelis, G, Krishnaprasad, K, Kugathasan, S, Kupcinskas, L, Latiano, A, Laukens, D, Lawrance, Ic, Lee, Jc, Lees, Cw, Leja, M, Van Limbergen, J, Lionetti, P, Liu, Jz, Louis, E, Mahy, G, Mansfield, J, Massey, D, Mathew, Cg, Mcgovern, Dp, Milgrom, R, Mitrovic, M, Montgomery, Gw, Mowat, C, Newman, W, Ng, A, Ng, Sc, Ng, Sm, Nikolaus, S, Ning, K, Nöthen, M, Oikonomou, I, Palmieri, O, Parkes, M, Phillips, A, Ponsioen, Cy, Potocnik, U, Prescott, Nj, Proctor, Dd, Radford Smith, G, Rahier, Jf, Raychaudhuri, S, Regueiro, M, Rieder, F, Rioux, Jd, Ripke, S, Roberts, R, Russell, Rk, Sanderson, Jd, Sans, M, Satsangi, J, Schadt, Ee, Schreiber, S, Schumm, Lp, Scott, R, Seielstad, M, Sharma, Y, Silverberg, Ms, Simms, La, Skieceviciene, J, Spain, Sl, Steinhart, A, Stempak, Jm, Stronati, Laura, Sventoraityte, J, Targan, Sr, Taylor, Km, ter Velde, A, Theatre, E, Torkvist, L, Tremelling, M, van der Meulen, A, van Sommeren, S, Vasiliauskas, E, Vermeire, S, Verspaget, Hw, Walters, T, Wang, K, Wang, Mh, Weersma, Rk, Wei, Z, Whiteman, D, Wijmenga, C, Wilson, Dc, Winkelmann, J, Xavier, Rj, Zeissig, S, Zhang, B, Zhang, Ck, Zhang, H, Zhang, W, Zhao, H, Zhao, Zz, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)

Subjects
Male, 0301 basic medicine, CLINICAL-COURSE, Nod2 Signaling Adaptor Protein, Disease, SUSCEPTIBILITY, Inflammatory bowel disease, Major Histocompatibility Complex, 0302 clinical medicine, Crohn Disease, Maintenance therapy, NOD2, Medicine and Health Sciences, POPULATION, Immunoassay, RISK, Medicine(all), education.field_of_study, Crohn's disease, Hepatocyte Growth Factor, Medicine (all), INDUCTION, Articles, General Medicine, PRIMARY SCLEROSING CHOLANGITIS, Ulcerative colitis, 3. Good health, Phenotype, Female, 030211 gastroenterology & hepatology, Adult, medicine.medical_specialty, MAINTENANCE THERAPY, Genotype, Population, Polymorphism, Single Nucleotide, Risk Assessment, CLASSIFICATION, Primary sclerosing cholangitis, Young Adult, 03 medical and health sciences, inflammatory bowel disease, Proto-Oncogene Proteins, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, education, Alleles, Genetic Association Studies, business.industry, medicine.disease, digestive system diseases, 030104 developmental biology, Immunology, Colitis, Ulcerative, business, FOLLOW-UP, HLA-DRB1 Chains, INFLAMMATORY-BOWEL-DISEASE
Abstract

Background: Crohn's disease and ulcerative colitis are the two major forms of inflammatory bowel disease; treatment strategies have historically been determined by this binary categorisation. Genetic studies have identified 163 susceptibility loci for inflammatory bowel disease, mostly shared between Crohn's disease and ulcerative colitis. We undertook the largest genotype association study, to date, in widely used clinical subphenotypes of inflammatory bowel disease with the goal of further understanding the biological relations between diseases.Methods: This study included patients from 49 centres in 16 countries in Europe, North America, and Australasia. We applied the Montreal classification system of inflammatory bowel disease subphenotypes to 34 819 patients (19 713 with Crohn's disease, 14 683 with ulcerative colitis) genotyped on the Immunochip array. We tested for genotype–phenotype associations across 156 154 genetic variants. We generated genetic risk scores by combining information from all known inflammatory bowel disease associations to summarise the total load of genetic risk for a particular phenotype. We used these risk scores to test the hypothesis that colonic Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetically distinct from each other, and to attempt to identify patients with a mismatch between clinical diagnosis and genetic risk profile.Findings: After quality control, the primary analysis included 29 838 patients (16 902 with Crohn's disease, 12 597 with ulcerative colitis). Three loci (NOD2, MHC, and MST1 3p21) were associated with subphenotypes of inflammatory bowel disease, mainly disease location (essentially fixed over time; median follow-up of 10·5 years). Little or no genetic association with disease behaviour (which changed dramatically over time) remained after conditioning on disease location and age at onset. The genetic risk score representing all known risk alleles for inflammatory bowel disease showed strong association with disease subphenotype (p=1·65 × 10−78), even after exclusion of NOD2, MHC, and 3p21 (p=9·23 × 10−18). Predictive models based on the genetic risk score strongly distinguished colonic from ileal Crohn's disease. Our genetic risk score could also identify a small number of patients with discrepant genetic risk profiles who were significantly more likely to have a revised diagnosis after follow-up (p=6·8 × 10−4).Interpretation: Our data support a continuum of disorders within inflammatory bowel disease, much better explained by three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's disease and ulcerative colitis as currently defined. Disease location is an intrinsic aspect of a patient's disease, in part genetically determined, and the major driver to changes in disease behaviour over time.Funding: International Inflammatory Bowel Disease Genetics Consortium members funding sources (see Acknowledgments for full list).

Published
2016
Full Text
View/download PDF

66. Evidence for PTGER4, PSCA and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level

Author

Hess, T, additional, Hamann, L, additional, Vashist, YK, additional, Butterbach, K, additional, Schmidt, T, additional, Krasniuk, I, additional, Höblinger, A, additional, Lingohr, P, additional, Ludwig, M, additional, Hagel, AF, additional, Schildberg, CW, additional, Veits, L, additional, Gyvyte, U, additional, Gonzalez-Carmona, MA, additional, Heinrichs, SK, additional, Becker, J, additional, Lordick, F, additional, Malfertheiner, P, additional, Möhler, M, additional, Pech, O, additional, Rodermann, E, additional, Izbicki, JR, additional, Kruschewski, M, additional, Ott, K, additional, Schumann, RR, additional, Vieth, M, additional, Mangold, E, additional, Kupcinskas, L, additional, Brenner, H, additional, Grimminger, P, additional, Bruns, C, additional, Büchler, MW, additional, Gockel, I, additional, Nöthen, MM, additional, Lippert, H, additional, Ridwelski, K, additional, Lanas, A, additional, Keller, G, additional, Knapp, M, additional, Leja, M, additional, Schumacher, J, additional, Kupcinskas, J, additional, García-González, MA, additional, and Venerito, M, additional

Published
2017
Full Text
View/download PDF

67. Eine Variante in COL3A1 (rs3134646) ist mit der Entstehung der Divertikulose bei Männern assoziiert

Author

Reichert, MC, additional, Kupcinskas, J, additional, Krawczyk, M, additional, Jüngst, C, additional, Grünhage, F, additional, Appenrodt, B, additional, Zimmer, V, additional, Weber, S, additional, Tamelis, A, additional, Lukosiene, JI, additional, Pauziene, N, additional, Kiudelis, G, additional, Jonaitis, L, additional, Schramm, C, additional, Göser, T, additional, Schulz, A, additional, Malinowski, M, additional, Glanemann, M, additional, Kupcinskas, L, additional, and Lammert, F, additional

Published
2017
Full Text
View/download PDF

68. Frequency of anaemia and anaemia subtypes in east-west European inception cohort : an ECCO-EpiCom cohort study

Author

Burisch, J., Gerdes, U., Almer, S., Cukovic-Cavka, S., Sebastian, S., Kaimakliotis, I., Duricova, D., Pedersen, N., Salupere, R., Nielsen, K. R., Manninen, P., Katsanos, K. H., Odes, S., Andersen, V., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Vinding, K. Kofod, Belousova, E., Ladefoged, K., Bailey, Y., Hernandez, V., Halfvarson, Jonas, Arebi, N., Shonova, O., Hoivik, M. L., Moum, B., Langholz, E., Lakatos, P. L., Munkholm, P., Dahlerup, J. F., Burisch, J., Gerdes, U., Almer, S., Cukovic-Cavka, S., Sebastian, S., Kaimakliotis, I., Duricova, D., Pedersen, N., Salupere, R., Nielsen, K. R., Manninen, P., Katsanos, K. H., Odes, S., Andersen, V., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Vinding, K. Kofod, Belousova, E., Ladefoged, K., Bailey, Y., Hernandez, V., Halfvarson, Jonas, Arebi, N., Shonova, O., Hoivik, M. L., Moum, B., Langholz, E., Lakatos, P. L., Munkholm, P., and Dahlerup, J. F.

Published
2016
Full Text
View/download PDF

69. Detection of Helicobacter Species in Consecutive Patients Refereed for Liver Biopsy

Author

Kupcinskas, L., Vitkauskiene, A., Petrenkiene, V., Gudinaviciene, I., and Wadstrom, T.

Subjects
Gastrointestinal diseases -- Research, Health, Research
Abstract

L. Kupcinskas [1] A. Vitkauskiene [1] V. Petrenkiene [1] I. Gudinaviciene [1] T. Wadstrom [2] [12/04] [*] Detection of Helicobacter Species in Consecutive Patients Refereed for Liver Biopsy Background: Helicabacter [...]

Published
2001

70. Relapse of Infection is Related with Insufficient Effective Eradication Regimen rather than High Prevalence of Helicobacter pylori (hp)

Author

Kupcinskas, L.

Subjects
Helicobacter infections -- Research, Helicobacter pylori -- Research, Gastrointestinal diseases -- Research, Health, Research
Abstract

[6/25] Relapse of Infection is Related with Insufficient Effective Eradication Regimen rather than High Prevalence of Helicobacter pylori (hp) Background: High relapse rate after eradication was reported in Africa and [...]

Published
2001

71. Trends in decreasing of Helicobacter pylori (HP) Prevalence in Lithuania

Author

Kupcinskas, L., Miciuleviciene, J., Kiudelis, G., Kucinskiene, R., and Jonaitis, L.V.

Subjects
Helicobacter infections -- Research, Helicobacter pylori -- Research, Gastrointestinal diseases -- Research, Health, Research
Abstract

[6/17] Trends in decreasing of Helicobacter pylori (HP) Prevalence in Lithuania Background: During last decades of previous century there was the significant decrease of HP prevalence in Western countries. Do [...]

Published
2001

72. PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): RESCUE TREATMENTS

Author

Axon, T., Lamy, V., Gisbert, J. P., McNicholl, A. G., Gasbarrini, A., Katicic, M., Machado, J. C., Boyanova, L., Przytulski, K., Simsek, I., Buzas, G. M., Tepes, B., Lerang, F., Bordin, D. S., Shvets, O., Beglinger, C., Capelle, L. G., Bytzer, P., Goldis, A., Rokkas, T., Kupcinskas, L., Ramas, M., O'Morain, C. A., Megraud, F., Caldas, M., Veijola, L., and Leja, M.

Published
2014

73. PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): SAFETY

Author

Katicic, M., Lamy, V., Axon, T., Gisbert, J. P., O'Morain, C. A., Megraud, F., Ramas, M., Caldas, M., Veijola, L., Capelle, L. G., Goldis, A., Bytzer, P., Beglinger, C., Buzas, G. M., Simsek, I., Przytulski, K., Boyanova, L., McNicholl, A. G., Gasbarrini, A., Tepes, B., Lerang, F., Bordin, D. S., Shvets, O., Rokkas, T., Kupcinskas, L., Leja, M., and Machado, J. C.

Published
2014

74. PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): INTERIM ANALYSIS OF 5792 PATIENTS

Author

Bordin, D. S., Lerang, F., McNicholl, A. G., Gasbarrini, A., Tepes, B., Rokkas, T., Buzas, G. M., Simsek, I., Przytulski, K., Boyanova, L., Machado, J. C., Katicic, M., Leja, M., Kupcinskas, L., Shvets, O., Axon, T., Gisbert, J. P., O'Morain, C. A., Megraud, F., Ramas, M., Caldas, M., Veijola, L., Cappelle, L. G., Goldis, A., Lamy, V., Bytzer, P., and Beglinger, C.

Published
2014

75. PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): FIRST-LINE TREATMENTS

Author

Shvets, O., Axon, T., Gisbert, J. P., O'Morain, C. A., Megraud, F., Ramas, M., Caldas, M., Veijola, L., Cappelle, L. G., Goldis, A., Lamy, V., Bytzer, P., Beglinger, C., Buzas, G. M., Simsek, I., Przytulski, K., Boyanova, L., Machado, J. C., Katicic, M., Leja, M., Kupcinskas, L., Rokkas, T., Bordin, D. S., Lerang, F., Tepes, B., Gasbarrini, A., and McNicholl, A. G.

Published
2014

76. Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals-3-year follow-up of the ECCO-EpiCom cohort

Author

Burisch, J., Kaimakliotis, I., Duricova, D., Kievit, L., Dahlerup, J. F., Salupere, R., Nielsen, K. R., Manninen, P., Tsianos, E. V., Vegh, Z., Odes, S., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Hernandez, V., Halfvarson, Jonas, Arebi, N., Langholz, E., Lakatos, P. L., Munkholm, P., EpiCom Northern Italy, Group author, Burisch, J., Kaimakliotis, I., Duricova, D., Kievit, L., Dahlerup, J. F., Salupere, R., Nielsen, K. R., Manninen, P., Tsianos, E. V., Vegh, Z., Odes, S., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Hernandez, V., Halfvarson, Jonas, Arebi, N., Langholz, E., Lakatos, P. L., Munkholm, P., and EpiCom Northern Italy, Group author

Abstract

Note: D'Inca R., On behalf of the EpiCom Northern Italy, Florence, Forlì, and Padova, Italy

Published
2015
Full Text
View/download PDF

78. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Author

Anderson, C.A. Boucher, G. Lees, C.W. Franke, A. D'Amato, M. Taylor, K.D. Lee, J.C. Goyette, P. Imielinski, M. Latiano, A. Lagacé, C. Scott, R. Amininejad, L. Bumpstead, S. Baidoo, L. Baldassano, R.N. Barclay, M. Bayless, T.M. Brand, S. Büning, C. Colombel, J.-F. Denson, L.A. De Vos, M. Dubinsky, M. Edwards, C. Ellinghaus, D. Fehrmann, R.S.N. Floyd, J.A.B. Florin, T. Franchimont, D. Franke, L. Georges, M. Glas, J. Glazer, N.L. Guthery, S.L. Haritunians, T. Hayward, N.K. Hugot, J.-P. Jobin, G. Laukens, D. Lawrance, I. Lémann, M. Levine, A. Libioulle, C. Louis, E. McGovern, D.P. Milla, M. Montgomery, G.W. Morley, K.I. Mowat, C. Ng, A. Newman, W. Ophoff, R.A. Papi, L. Palmieri, O. Peyrin-Biroulet, L. Panés, J. Phillips, A. Prescott, N.J. Proctor, D.D. Roberts, R. Russell, R. Rutgeerts, P. Sanderson, J. Sans, M. Schumm, P. Seibold, F. Sharma, Y. Simms, L.A. Seielstad, M. Steinhart, A.H. Targan, S.R. Van Den Berg, L.H. Vatn, M. Verspaget, H. Walters, T. Wijmenga, C. Wilson, D.C. Westra, H.-J. Xavier, R.J. Zhao, Z.Z. Ponsioen, C.Y. Andersen, V. Torkvist, L. Gazouli, M. Anagnou, N.P. Karlsen, T.H. Kupcinskas, L. Sventoraityte, J. Mansfield, J.C. Kugathasan, S. Silverberg, M.S. Halfvarson, J. Rotter, J.I. Mathew, C.G. Griffiths, A.M. Gearry, R. Ahmad, T. Brant, S.R. Chamaillard, M. Satsangi, J. Cho, J.H. Schreiber, S. Daly, M.J. Barrett, J.C. Parkes, M. Annese, V. Hakonarson, H. Radford-Smith, G. Duerr, R.H. Vermeire, S. Weersma, R.K. Rioux, J.D.

Abstract

Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10-8), increasing the number of ulcerative colitis-associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis. © 2011 Nature America, Inc. All rights reserved.

Published
2011

79. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL)

Author

Franke, A. Balschun, T. Sina, C. Ellinghaus, D. Häsler, R. Mayr, G. Albrecht, M. Wittig, M. Buchert, E. Nikolaus, S. Gieger, C. Wichmann, H.E. Sventoraityte, J. Kupcinskas, L. Onnie, C.M. Gazouli, M. Anagnou, N.P. Strachan, D. McArdle, W.L. Mathew, C.G. Rutgeerts, P. Vermeire, S. Vatn, M.H. Krawczak, M. Rosenstiel, P. Karlsen, T.H. Schreiber, S.

Abstract

We performed a genome-wide association analysis of 1,897,764 SNPs in 1,043 German ulcerative colitis (UC) cases and 1,703 controls. We discovered new associations at chromosome 7q22 (rs7809799) and at chromosome 22q13 in IL17REL (rs5771069) and confirmed these associations in six replication panels (2,539 UC cases and 5,428 controls) from different regions of Europe (overall study sample P rs7809799 = 8.81 × 10 -11 and P rs5771069 = 4.21 × 10 -8, respectively). © 2010 Nature America, Inc. All rights reserved.

Published
2010

80. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

Author

Burisch, J., Pedersen, N., Cukovic-Cavka, S., Brinar, M., Kaimakliotis, I., Duricova, D., Shonova, O., Vind, I., Avnstrom, S., Thorsgaard, N., Andersen, V., Krabbe, S., Dahlerup, J.F., Salupere, R., Nielsen, K.R., Olsen, J., Manninen, P., Collin, P., Tsianos, E.V., Katsanos, K.H., Ladefoged, K., Lakatos, L., Bjornsson, E., Ragnarsson, G., Bailey, Y., Odes, S., Schwartz, D., Martinato, M., Lupinacci, G., Milla, M., De Padova, A., D'lnca, R., Beltrami, M., Kupcinskas, L., Kiudelis, G., Turcan, S., Tighineanu, O., Mihu, I., Magro, F., Barros, L.F., Goldis, A., Lazar, D., Belousova, E., Nikulina, I., Hernandez, V., Martinez-Ares, D., Almer, Sven, Zhulina, Y., Halfvarson, J., Arebi, N., Sebastian, S., Lakatos, P.L., Langholz, E., Munkholm, P., Burisch, J., Pedersen, N., Cukovic-Cavka, S., Brinar, M., Kaimakliotis, I., Duricova, D., Shonova, O., Vind, I., Avnstrom, S., Thorsgaard, N., Andersen, V., Krabbe, S., Dahlerup, J.F., Salupere, R., Nielsen, K.R., Olsen, J., Manninen, P., Collin, P., Tsianos, E.V., Katsanos, K.H., Ladefoged, K., Lakatos, L., Bjornsson, E., Ragnarsson, G., Bailey, Y., Odes, S., Schwartz, D., Martinato, M., Lupinacci, G., Milla, M., De Padova, A., D'lnca, R., Beltrami, M., Kupcinskas, L., Kiudelis, G., Turcan, S., Tighineanu, O., Mihu, I., Magro, F., Barros, L.F., Goldis, A., Lazar, D., Belousova, E., Nikulina, I., Hernandez, V., Martinez-Ares, D., Almer, Sven, Zhulina, Y., Halfvarson, J., Arebi, N., Sebastian, S., Lakatos, P.L., Langholz, E., and Munkholm, P.

Abstract

Objective The incidence of inflammatory bowel disease (IBD) is increasing in Eastern Europe. The reasons for these changes remain unknown. The aim of this study was to investigate whether an East–West gradient in the incidence of IBD in Europe exists. Design A prospective, uniformly diagnosed, population based inception cohort of IBD patients in 31 centres from 14 Western and eight Eastern European countries covering a total background population of approximately 10.1 million people was created. One-third of the centres had previous experience with inception cohorts. Patients were entered into a low cost, web based epidemiological database, making participation possible regardless of socioeconomic status and prior experience. Results 1515 patients aged 15 years or older were included, of whom 535 (35%) were diagnosed with Crohn's disease (CD), 813 (54%) with ulcerative colitis (UC) and 167 (11%) with IBD unclassified (IBDU). The overall incidence rate ratios in all Western European centres were 1.9 (95% CI 1.5 to 2.4) for CD and 2.1 (95% CI 1.8 to 2.6) for UC compared with Eastern European centres. The median crude annual incidence rates per 100 000 in 2010 for CD were 6.5 (range 0–10.7) in Western European centres and 3.1 (range 0.4–11.5) in Eastern European centres, for UC 10.8 (range 2.9–31.5) and 4.1 (range 2.4–10.3), respectively, and for IBDU 1.9 (range 0–39.4) and 0 (range 0–1.2), respectively. In Western Europe, 92% of CD, 78% of UC and 74% of IBDU patients had a colonoscopy performed as the diagnostic procedure compared with 90%, 100% and 96%, respectively, in Eastern Europe. 8% of CD and 1% of UC patients in both regions underwent surgery within the first 3 months of the onset of disease. 7% of CD patients and 3% of UC patients from Western Europe received biological treatment as rescue therapy. Of all European CD patients, 20% received only 5-aminosalicylates as induction therapy. Conclusions An East–West gradient in IBD incidence exists in Europe. Among

Published
2014
Full Text
View/download PDF

81. The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era : An ECCO-EpiCom study

Author

Burisch, J., Kaimakliotis, I., Duricova, D., Thorsgaard, N., Andersen, V., Nielsen, K. R., Tsianos, E. V., Ladefoged, K., Bailey, Y., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Belousova, E., Hernandez, V., Almer, S., Halfvarson, Jonas, Sebastian, S., Langholz, E., Odes, S., Munkholm, P., Burisch, J., Kaimakliotis, I., Duricova, D., Thorsgaard, N., Andersen, V., Nielsen, K. R., Tsianos, E. V., Ladefoged, K., Bailey, Y., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Belousova, E., Hernandez, V., Almer, S., Halfvarson, Jonas, Sebastian, S., Langholz, E., Odes, S., and Munkholm, P.

Published
2014
Full Text
View/download PDF

82. Health care and patients' education in a European inflammatory bowel disease inception cohort:An ECCO-EpiCom study

Author

Burisch, J, Vegh, Z, Pedersen, Natalia, Cuković-Čavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Politi, P, Santini, A, Kiudelis, G, Kupcinskas, L, Turcan, S, Magro, F, Barros, L, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Sanromán, L, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Houston, Y, Sebastian, S, Langholz, E, Lakatos, P L, Munkholm, P, Burisch, J, Vegh, Z, Pedersen, Natalia, Cuković-Čavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Politi, P, Santini, A, Kiudelis, G, Kupcinskas, L, Turcan, S, Magro, F, Barros, L, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Sanromán, L, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Houston, Y, Sebastian, S, Langholz, E, Lakatos, P L, and Munkholm, P

Abstract

BACKGROUND AND AIMS: The EpiCom study and inception cohort was initiated in 2010 in 31 centers from 14 Western and 8 Eastern European countries, covering a 10.1million person background population. Our aim was to investigate whether there is a difference between Eastern and Western Europe in health care and education of patients with inflammatory bowel disease (IBD).METHODS: A quality of care (QoC) questionnaire was developed in the EpiCom group consisting of 16 questions covering 5 items: time interval between the onset of symptoms and diagnosis, information, education, empathy and access to health care providers.RESULTS: Of 1,515 patients, 947 (217 east/730 west) answered the QoC questionnaire. Only 23% of all patients had knowledge about IBD before diagnosis. In Eastern Europe, significantly more patients searched out information about IBD themselves (77% vs. 68%, p<0.05), the main source was the Internet (92% vs. 88% p=0.23). In Western Europe, significantly more patients were educated by nurses (19% vs. 1%, p<0.05), while in Eastern Europe, gastroenterologists were easier to contact (80% vs. 68%, p<0.05).CONCLUSION: Health care differed significantly between Eastern and Western Europe in all items, but satisfaction rates were high in both geographic regions. Because of the low awareness and the rising incidence of IBD, general information should be the focus of patient organizations and medical societies. In Western Europe IBD nurses play a very important role in reducing the burden of patient management.

Published
2014

83. East-West gradient in the incidence of inflammatory bowel disease in Europe:the ECCO-EpiCom inception cohort

Author

Burisch, J, Pedersen, Natalia, Čuković-Čavka, S, Brinar, M, Kaimakliotis, I, Duricova, D, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Andersen, Vinnie, Krabbe, S, Dahlerup, J F, Salupere, R, Nielsen, K R, Olsen, J, Manninen, P, Collin, P, Tsianos, E V, Katsanos, K H, Ladefoged, K, Lakatos, L, Björnsson, E, Ragnarsson, G, Bailey, Y, Odes, S, Schwartz, D, Martinato, M, Lupinacci, G, Milla, M, De Padova, A, D'Incà, R, Beltrami, M, Kupcinskas, L, Kiudelis, G, Turcan, S, Tighineanu, O, Mihu, I, Magro, F, Barros, L F, Goldis, A, Lazar, D, Belousova, E, Nikulina, I, Hernandez, V, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Munkholm, P, Burisch, J, Pedersen, Natalia, Čuković-Čavka, S, Brinar, M, Kaimakliotis, I, Duricova, D, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Andersen, Vinnie, Krabbe, S, Dahlerup, J F, Salupere, R, Nielsen, K R, Olsen, J, Manninen, P, Collin, P, Tsianos, E V, Katsanos, K H, Ladefoged, K, Lakatos, L, Björnsson, E, Ragnarsson, G, Bailey, Y, Odes, S, Schwartz, D, Martinato, M, Lupinacci, G, Milla, M, De Padova, A, D'Incà, R, Beltrami, M, Kupcinskas, L, Kiudelis, G, Turcan, S, Tighineanu, O, Mihu, I, Magro, F, Barros, L F, Goldis, A, Lazar, D, Belousova, E, Nikulina, I, Hernandez, V, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, and Munkholm, P

Abstract

OBJECTIVE: The incidence of inflammatory bowel disease (IBD) is increasing in Eastern Europe. The reasons for these changes remain unknown. The aim of this study was to investigate whether an East-West gradient in the incidence of IBD in Europe exists.DESIGN: A prospective, uniformly diagnosed, population based inception cohort of IBD patients in 31 centres from 14 Western and eight Eastern European countries covering a total background population of approximately 10.1 million people was created. One-third of the centres had previous experience with inception cohorts. Patients were entered into a low cost, web based epidemiological database, making participation possible regardless of socioeconomic status and prior experience.RESULTS: 1515 patients aged 15 years or older were included, of whom 535 (35%) were diagnosed with Crohn's disease (CD), 813 (54%) with ulcerative colitis (UC) and 167 (11%) with IBD unclassified (IBDU). The overall incidence rate ratios in all Western European centres were 1.9 (95% CI 1.5 to 2.4) for CD and 2.1 (95% CI 1.8 to 2.6) for UC compared with Eastern European centres. The median crude annual incidence rates per 100,000 in 2010 for CD were 6.5 (range 0-10.7) in Western European centres and 3.1 (range 0.4-11.5) in Eastern European centres, for UC 10.8 (range 2.9-31.5) and 4.1 (range 2.4-10.3), respectively, and for IBDU 1.9 (range 0-39.4) and 0 (range 0-1.2), respectively. In Western Europe, 92% of CD, 78% of UC and 74% of IBDU patients had a colonoscopy performed as the diagnostic procedure compared with 90%, 100% and 96%, respectively, in Eastern Europe. 8% of CD and 1% of UC patients in both regions underwent surgery within the first 3 months of the onset of disease. 7% of CD patients and 3% of UC patients from Western Europe received biological treatment as rescue therapy. Of all European CD patients, 20% received only 5-aminosalicylates as induction therapy.CONCLUSIONS: An East-West gradient in IBD incidence

Published
2014

84. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe:An ECCO-EpiCom study

Author

Burisch, J, Pedersen, Natalia, Cukovic-Cavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Lakatos, L, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Giannotta, M, Girardin, G, Kiudelis, G, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Martinez-Ares, D, Hernandez, V, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Tsai, H H, Langholz, E, Munkholm, P, Burisch, J, Pedersen, Natalia, Cukovic-Cavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Lakatos, L, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Giannotta, M, Girardin, G, Kiudelis, G, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Martinez-Ares, D, Hernandez, V, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Tsai, H H, Langholz, E, and Munkholm, P

Abstract

BACKGROUND AND AIMS: The incidence of inflammatory bowel disease (IBD) is increasing in Eastern Europe possibly due to changes in environmental factors towards a more "westernised" standard of living. The aim of this study was to investigate differences in exposure to environmental factors prior to diagnosis in Eastern and Western European IBD patients.METHODS: The EpiCom cohort is a population-based, prospective inception cohort of 1560 unselected IBD patients from 31 European countries covering a background population of 10.1 million. At the time of diagnosis patients were asked to complete an 87-item questionnaire concerning environmental factors.RESULTS: A total of 1182 patients (76%) answered the questionnaire, 444 (38%) had Crohn's disease (CD), 627 (53%) ulcerative colitis (UC), and 111 (9%) IBD unclassified. No geographic differences regarding smoking status, caffeine intake, use of oral contraceptives, or number of first-degree relatives with IBD were found. Sugar intake was higher in CD and UC patients from Eastern Europe than in Western Europe while fibre intake was lower (p<0.01). Daily consumption of fast food as well as appendectomy before the age of 20 was more frequent in Eastern European than in Western European UC patients (p<0.01). Eastern European CD and UC patients had received more vaccinations and experienced fewer childhood infections than Western European patients (p<0.01).CONCLUSIONS: In this European population-based inception cohort of unselected IBD patients, Eastern and Western European patients differed in environmental factors prior to diagnosis. Eastern European patients exhibited higher occurrences of suspected risk factors for IBD included in the Western lifestyle.

Published
2014

85. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia:Results of the 2011 ECCO-EpiCom inception cohort

Author

Vegh, Z, Burisch, J., Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Avnstrøm, S, Vinding, K Kofod, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Tighineanu, O, Mihu, I, Barros, L F, Magro, F, Lazar, D, Goldis, A, Fernandez, A, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, Lakatos, P L, Vegh, Z, Burisch, J., Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Avnstrøm, S, Vinding, K Kofod, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Tighineanu, O, Mihu, I, Barros, L F, Magro, F, Lazar, D, Goldis, A, Fernandez, A, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, and Lakatos, P L

Abstract

BACKGROUND AND AIMS: The aim of the present study was to validate the IBD (inflammatory bowel diseases) incidence reported in the 2010 ECCO-EpiCom (European Crohn's and Colitis Organization-Epidemiological Committee) inception cohort by including a second independent inception cohort from participating centers in 2011 and an Australian center to investigate whether there is a difference in the incidence of IBD between Eastern and Western European countries and Australia.METHODS: Fourteen centers from 5 Eastern and 9 Western European countries and one center from Australia participated in the ECCO-EpiCom 2011 inception cohort. Patients' data regarding disease type, socio-demographic factors, extraintestinal manifestations and therapy were entered into the Web-based EpiCom database, www.ecco-epicom.eu.RESULTS: A total of 711 adult patients were diagnosed during the inclusion year 2011, 178 (25%) from Eastern, 461 (65%) from Western Europe and 72 (10%) from Australia; 259 (37%) patients were diagnosed with Crohn's disease, 380 (53%) with ulcerative colitis and 72 (10%) with IBD unclassified. The mean annual incidence rate for IBD was 11.3/100,000 in Eastern Europe, 14.0/100,000 in Western Europe and 30.3/100,000 in Australia. Significantly more patients were diagnosed with complicated disease at diagnosis in Eastern Europe compared to Western Europe (43% vs. 27%, p=0.02).CONCLUSION: Incidence rates, disease phenotype and initial treatment characteristics in the 2011 ECCO-EpiCom cohort were not significantly different from that reported in the 2010 cohort.

Published
2014

86. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease:An ECCO-EpiCom study

Author

Burisch, J, Weimers, P, Pedersen, N, Cukovic-Cavka, S, Vucelic, B, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, Vinnie, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Lakatos, L, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Valpiani, D, Boni, M C, Jonaitis, L, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Fernandez, A, Sanroman, L, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Diggory, T, Munkholm, P, Burisch, J, Weimers, P, Pedersen, N, Cukovic-Cavka, S, Vucelic, B, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, Ida, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, Vinnie, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Lakatos, L, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Valpiani, D, Boni, M C, Jonaitis, L, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Fernandez, A, Sanroman, L, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Diggory, T, and Munkholm, P

Abstract

BACKGROUND & AIMS: Health-related quality of life (HRQoL) is impaired in patients with Inflammatory Bowel Disease (IBD). The aim was prospectively to assess and validate the pattern of HRQoL in an unselected, population-based inception cohort of IBD patients from Eastern and Western Europe.METHODS: The EpiCom inception cohort consists of 1560 IBD patients from 31 European centres covering a background population of approximately 10.1 million. Patients answered the disease specific Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and generic Short Form 12 (SF-12) questionnaire at diagnosis and after one year of follow-up.RESULTS: In total, 1079 patients were included in this study. Crohn's disease (CD) patients mean SIBDQ scores improved from 45.3 to 55.3 in Eastern Europe and from 44.9 to 53.6 in Western Europe. SIBDQ scores for ulcerative colitis (UC) patients improved from 44.9 to 57.4 and from 48.8 to 55.7, respectively. UC patients needing surgery or biologicals had lower SIBDQ scores before and after compared to the rest, while biological therapy improved SIBDQ scores in CD. CD and UC patients in both regions improved all SF-12 scores. Only Eastern European UC patients achieved SF-12 summary scores equal to or above the normal population.CONCLUSION: Medical and surgical treatment improved HRQoL during the first year of disease. The majority of IBD patients in both Eastern and Western Europe reported a positive perception of disease-specific but not generic HRQoL. Biological therapy improved HRQoL in CD patients, while UC patients in need of surgery or biological therapy experienced lower perceptions of HRQoL than the rest.

Published
2014

88. OP008 The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study

Author

Burisch, J., primary, Kaimakliotis, I., additional, Duricova, D., additional, Thorsgaard, N., additional, Andersen, V., additional, Nielsen, K.R., additional, Tsianos, E.V., additional, Ladefoged, K., additional, Bailey, Y., additional, D'incà, R., additional, Kupcinskas, L., additional, Turcan, S., additional, Magro, F., additional, Goldis, A., additional, Belousova, E., additional, Hernandez, V., additional, Almer, S., additional, Halfvarson, J., additional, Sebastian, S., additional, Langholz, E., additional, Odes, S., additional, and Munkholm, P., additional

Published
2014
Full Text
View/download PDF

89. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe

Author

Boyanova, L Mentis, A Gubina, M Rozynek, E Gosciniak, G and Kalenic, S Goral, V Kupcinskas, L Kantarceken, B and Aydin, A Archimandritis, A Dzierzanowska, D Vcev, A and Ivanova, K Marina, M Mitov, I Petrov, P Ozden, A and Popova, M

Abstract

Objective To evaluate the primary, secondary and combined resistance to five antimicrobial agents of 2340 Helicobacter pylori isolates from 19 centers in 10 countries in eastern Europe. Methods Data were available for centers in Bulgaria, Croatia, the Czech Republic, Estonia, Greece, Lithuania, Poland, Russia, Slovenia and Turkey. Susceptibility was tested by agar dilution (seven countries), E test (five countries) and disk diffusion (three countries) methods. Resistance breakpoints (mg/L) were: metronidazole 8, clarithromycin 1, amoxicillin 0.5, tetracycline 4, and ciprofloxacin 1 or 4 in most centers. Primary and post-treatment resistance was assessed in 2003 and 337 isolates respectively. Results for 282 children and 201 adults were compared. Results Primary resistance rates since 1998 were: metronidazole 37.9%, clarithromycin 9.5%, amoxicillin 0.9%, tetracycline 1.9%, ciprofloxacin 3.9%, and both metronidazole and clarithromycin 6.1%. Isolates from centers in Slovenia and Lithuania exhibited low resistance rates. Since 1998, amoxicillin resistance has been detected in the southeastern region. From 1996, metronidazole resistance increased significantly from 30.5% to 36.4%, while clarithromycin resistance increased slightly from 8.9% to 10.6%. In centers in Greece, Poland, and Bulgaria, the mean metronidazole resistance was slightly higher in adults than in children (39% versus 31.2%, P > 0.05); this trend was not found for clarithromycin or amoxicillin (P > 0.20). Post-treatment resistance rates exhibited wide variations. Conclusions In eastern Europe, primary H. pylori resistance to metronidazole is considerable, and that to clarithromycin is similar to or slightly higher than that in western Europe. Resistance to amoxicillin, ciprofloxacin and tetracycline was detected in several centers. Primary and post-treatment resistance rates vary greatly between centers.

Published
2002

90. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Author

Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S.L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., Achkar, J.P., Ahmad, T., Amininejad, L., Ananthakrishnan, A.N., Andersen, V., Andrews, J.M., Baidoo, L., Balschun, T., Bampton, P.A., Bitton, A., Boucher, G., Brand, S., Buning, C., Cohain, A., Cichon, S., D'Amato, M., Jong, D.J. de, Devaney, K.L., Dubinsky, M.C., Edwards, C., Ellinghaus, D., Ferguson, L.R., Franchimont, D., Fransen, K., Gearry, R.B., Georges, M., Gieger, C., Glas, J., Haritunians, T., Hart, A., Hawkey, C.J., Hedl, M., Hu, X., Karlsen, T.H., Kupcinskas, L., Kugathasan, S., Latiano, A., Laukens, D., Lawrance, I.C., Lees, C.W., Louis, E., Mahy, G., Mansfield, J., Morgan, A.R., Mowat, C., Newman, W.G., Palmieri, O., Ponsioen, C.Y., Potocnik, U., Prescott, N.J., Regueiro, M., Rotter, J.I., Russell, R.K., Sanderson, J.D., Sans, M., Satsangi, J., Schreiber, S., Simms, L.A., Sventoraityte, J., Targan, S.R., Taylor, K.D., Tremelling, M., Verspaget, H.W., Vos, M de, Wijmenga, C., Winkelmann, J., Wilson, D.C., Xavier, R.J., Zeissig, S., Zhang, B., Zhang, C.K., Zhao, H., Silverberg, M.S., Annesse, V., Hakonarson, H., Brant, S.R., Radford-Smith, G., Mathew, C.G., Rioux, J.D., Schadt, E.E., Daly, M.J., Franke, A., Parkes, M., Vermeire, S., Barrett, J.C., Cho, J.H., Donnelly, J.P., et al., Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S.L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., Achkar, J.P., Ahmad, T., Amininejad, L., Ananthakrishnan, A.N., Andersen, V., Andrews, J.M., Baidoo, L., Balschun, T., Bampton, P.A., Bitton, A., Boucher, G., Brand, S., Buning, C., Cohain, A., Cichon, S., D'Amato, M., Jong, D.J. de, Devaney, K.L., Dubinsky, M.C., Edwards, C., Ellinghaus, D., Ferguson, L.R., Franchimont, D., Fransen, K., Gearry, R.B., Georges, M., Gieger, C., Glas, J., Haritunians, T., Hart, A., Hawkey, C.J., Hedl, M., Hu, X., Karlsen, T.H., Kupcinskas, L., Kugathasan, S., Latiano, A., Laukens, D., Lawrance, I.C., Lees, C.W., Louis, E., Mahy, G., Mansfield, J., Morgan, A.R., Mowat, C., Newman, W.G., Palmieri, O., Ponsioen, C.Y., Potocnik, U., Prescott, N.J., Regueiro, M., Rotter, J.I., Russell, R.K., Sanderson, J.D., Sans, M., Satsangi, J., Schreiber, S., Simms, L.A., Sventoraityte, J., Targan, S.R., Taylor, K.D., Tremelling, M., Verspaget, H.W., Vos, M de, Wijmenga, C., Winkelmann, J., Wilson, D.C., Xavier, R.J., Zeissig, S., Zhang, B., Zhang, C.K., Zhao, H., Silverberg, M.S., Annesse, V., Hakonarson, H., Brant, S.R., Radford-Smith, G., Mathew, C.G., Rioux, J.D., Schadt, E.E., Daly, M.J., Franke, A., Parkes, M., Vermeire, S., Barrett, J.C., Cho, J.H., Donnelly, J.P., and et al.

Abstract

Item does not contain fulltext

Published
2012

91. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Author

Anderson, CA, Boucher, G, Lees, CW, Franke, A, D'Amato, M, Taylor, KD, Lee, JC, Goyette, P, Imielinski, M, Latiano, A, Lagace, C, Scott, R, Amininejad, L, Bumpstead, S, Baidoo, L, Baldassano, RN, Barclay, M, Bayless, TM, Brand, S, Buening, C, Colombel, J-F, Denson, LA, De Vos, M, Dubinsky, M, Edwards, C, Ellinghaus, D, Fehrmann, RSN, Floyd, JAB, Florin, T, Franchimont, D, Franke, L, Georges, M, Glas, J, Glazer, NL, Guthery, SL, Haritunians, T, Hayward, NK, Hugot, J-P, Jobin, G, Laukens, D, Lawrance, I, Lemann, M, Levine, A, Libioulle, C, Louis, E, McGovern, DP, Milla, M, Montgomery, GW, Morley, KI, Mowat, C, Ng, A, Newman, W, Ophoff, RA, Papi, L, Palmieri, O, Peyrin-Biroulet, L, Panes, J, Phillips, A, Prescott, NJ, Proctor, DD, Roberts, R, Russell, R, Rutgeerts, P, Sanderson, J, Sans, M, Schumm, P, Seibold, F, Sharma, Y, Simms, LA, Seielstad, M, Steinhart, AH, Targan, SR, van den Berg, LH, Vatn, M, Verspaget, H, Walters, T, Wijmenga, C, Wilson, DC, Westra, H-J, Xavier, RJ, Zhao, ZZ, Ponsioen, CY, Andersen, V, Torkvist, L, Gazouli, M, Anagnou, NP, Karlsen, TH, Kupcinskas, L, Sventoraityte, J, Mansfield, JC, Kugathasan, S, Silverberg, MS, Halfvarson, J, Rotter, JI, Mathew, CG, Griffiths, AM, Gearry, R, Ahmad, T, Brant, SR, Chamaillard, M, Satsangi, J, Cho, JH, Schreiber, S, Daly, MJ, Barrett, JC, Parkes, M, Annese, V, Hakonarson, H, Radford-Smith, G, Duerr, RH, Vermeire, S, Weersma, RK, Rioux, JD, Anderson, CA, Boucher, G, Lees, CW, Franke, A, D'Amato, M, Taylor, KD, Lee, JC, Goyette, P, Imielinski, M, Latiano, A, Lagace, C, Scott, R, Amininejad, L, Bumpstead, S, Baidoo, L, Baldassano, RN, Barclay, M, Bayless, TM, Brand, S, Buening, C, Colombel, J-F, Denson, LA, De Vos, M, Dubinsky, M, Edwards, C, Ellinghaus, D, Fehrmann, RSN, Floyd, JAB, Florin, T, Franchimont, D, Franke, L, Georges, M, Glas, J, Glazer, NL, Guthery, SL, Haritunians, T, Hayward, NK, Hugot, J-P, Jobin, G, Laukens, D, Lawrance, I, Lemann, M, Levine, A, Libioulle, C, Louis, E, McGovern, DP, Milla, M, Montgomery, GW, Morley, KI, Mowat, C, Ng, A, Newman, W, Ophoff, RA, Papi, L, Palmieri, O, Peyrin-Biroulet, L, Panes, J, Phillips, A, Prescott, NJ, Proctor, DD, Roberts, R, Russell, R, Rutgeerts, P, Sanderson, J, Sans, M, Schumm, P, Seibold, F, Sharma, Y, Simms, LA, Seielstad, M, Steinhart, AH, Targan, SR, van den Berg, LH, Vatn, M, Verspaget, H, Walters, T, Wijmenga, C, Wilson, DC, Westra, H-J, Xavier, RJ, Zhao, ZZ, Ponsioen, CY, Andersen, V, Torkvist, L, Gazouli, M, Anagnou, NP, Karlsen, TH, Kupcinskas, L, Sventoraityte, J, Mansfield, JC, Kugathasan, S, Silverberg, MS, Halfvarson, J, Rotter, JI, Mathew, CG, Griffiths, AM, Gearry, R, Ahmad, T, Brant, SR, Chamaillard, M, Satsangi, J, Cho, JH, Schreiber, S, Daly, MJ, Barrett, JC, Parkes, M, Annese, V, Hakonarson, H, Radford-Smith, G, Duerr, RH, Vermeire, S, Weersma, RK, and Rioux, JD

Abstract

Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10(-8)), increasing the number of ulcerative colitis-associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis.

Published
2011

92. Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial.

Author

van Rensburg, C, Barkun, A N, Racz, I, Fedorak, R, Bornman, P C, Beglinger, Christoph, Balanzó, J, Devière, Jacques, Kupcinskas, L, Luehmann, R, Doerfler, H, Schäfer-Preuss, S, van Rensburg, C, Barkun, A N, Racz, I, Fedorak, R, Bornman, P C, Beglinger, Christoph, Balanzó, J, Devière, Jacques, Kupcinskas, L, Luehmann, R, Doerfler, H, and Schäfer-Preuss, S

Abstract

BACKGROUND: Controlled pantoprazole data in peptic ulcer bleeding are few. AIM: To compare intravenous (IV) pantoprazole with IV ranitidine for bleeding ulcers. METHODS: After endoscopic haemostasis, 1256 patients were randomized to pantoprazole 80 mg+8 mg/h or ranitidine 50 mg+13 mg/h, both for 72 h. Patients underwent second-look endoscopy on day 3 or earlier, if clinically indicated. The primary endpoint was an overall outcome ordinal score: no rebleeding, rebleeding without/with subsequent haemostasis, surgery and mortality. The latter three events were also assessed separately and together. RESULTS: There were no between-group differences in overall outcome scores (pantoprazole vs. ranitidine: S0: 91.2 vs. 89.3%, S1: 1.5 vs. 2.5%, S2: 5.4 vs. 5.7%, S3: 1.7 vs. 2.1%, S4: 0.19 vs. 0.38%, P = 0.083), 72-h clinically detected rebleeding (2.9% [95% CI 1.7, 4.6] vs. 3.2% [95% CI 2.0, 4.9]), surgery (1.9% [95% CI 1.0, 3.4] vs. 2.1% [95% CI 1.1, 3.5]) or day-3 mortality (0.2% [95% CI 0, 0.09] vs. 0.3% [95% CI 0, 1.1]). Pantoprazole significantly decreased cumulative frequencies of events comprising the ordinal score in spurting lesions (13.9% [95% CI 6.6, 24.7] vs. 33.9% [95% CI 22.1, 47.4]; P = 0.01) and gastric ulcers (6.7% [95% CI 4, 10.4] vs. 14.3% [95% CI 10.3, 19.2], P = 0.006). CONCLUSIONS: Outcomes amongst pantoprazole and ranitidine-treated patients were similar; pantoprazole provided benefits in patients with arterial spurting and gastric ulcers., Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, FLWIN, info:eu-repo/semantics/published

Published
2009

93. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: a prospective, randomized, double blind, and placebo-controlled study5

Author

Kupcinskas, L., Lafolie, P., Lignell, A., Kiudelis, G., Jonaitis, L., Adamonis, K., Wadstrom, T., Andersen, Leif Percival, Kupcinskas, L., Lafolie, P., Lignell, A., Kiudelis, G., Jonaitis, L., Adamonis, K., Wadstrom, T., and Andersen, Leif Percival

Abstract

OBJECTIVES: The aim of this study was to evaluate the efficacy of the natural antioxidant astaxanthin in functional dyspepsia in different doses and compared with placebo. DESIGN: The study was a controlled, prospective, randomized, and double blind trial. PARTICIPANTS: Patients with functional dyspepsia, divided into three groups with 44 individuals in each group (placebo, 16mg, or 40mg astaxanthin, respectively). INTERVENTIONS: Participants were asked to accept gastroscopy before treatment, together with questionnaires: GSRS and SF-36. Urea breath test (UBT) was done before the treatment. MAIN OUTCOME: The primary objective was to test the hypothesis that the antioxidant astaxanthin at two doses regimens compared to placebo should ameliorate gastrointestinal discomfort measured as GSRS in patients with functional dyspepsia, who were either positive or negative for Helicobacter pylori, after 4 weeks of treatment. RESULTS: At the end of therapy (week 4) no difference between the three treatment groups was observed regarding mean Gastrointestinal Symptom Rating Scale (GSRS) scores of abdominal pain, indigestion and reflux syndromes. The same results were observed at the end of follow-up. However reduction of reflux syndrome before treatment to week 4 was significantly pronounced in the higher (40mg) dose compared to the other treatment groups (16mg and placebo, p=0.04). CONCLUSION: In general, no curative effect of astaxanthin was found in functional dyspepsia patients. Significantly greater reduction of reflux symptoms were detected in patients treated with the highest dose of the natural antioxidant astaxanthin. The response was more pronounced in H. pylori-infected patients Udgivelsesdato: 2008/6

Published
2008

95. P648 Environmental factors prior to IBD diagnosis in Europe – an ECCO–EpiCom study

Author

Burisch, J., primary, Seerup, R., additional, Cukovic-Cavka, S., additional, Kaimakliotis, I., additional, Duricova, D., additional, Shonova, O., additional, Vind, I., additional, Pedersen, N., additional, Langholz, E., additional, Thorsgaard, N., additional, Andersen, V., additional, Dahlerup, J.F., additional, Salupere, R., additional, Nielsen, K.R., additional, Manninen, P., additional, Tsianos, E., additional, Ladefoged, K., additional, Björnsson, E., additional, Bailey, Y., additional, Odes, S., additional, Martinato, M., additional, Kupcinskas, L., additional, Turcan, S., additional, Magro, F., additional, Goldis, A., additional, Belousova, E., additional, Hernandez, V., additional, Almer, S., additional, Halfvarson, J., additional, Arebi, N., additional, Sebastian, S., additional, Lakatos, P., additional, and Munkholm, P., additional

Published
2013
Full Text
View/download PDF

98. P510 European multicenter trial of budesonide and mesalazine for short-term treatment of active collagenous colitis (BUC60/COC)

Author

Miehlke, S., primary, Madisch, A., additional, Kupcinskas, L., additional, Petrauskas, D., additional, Heptner, G., additional, Böhm, G., additional, Marks, H.-J., additional, Neumeyer, M., additional, Nathan, T., additional, Fernández-Bañares, F., additional, Greinwald, R., additional, Mohrbacher, R., additional, Vieth, M., additional, and Bonderup, O., additional

Published
2013
Full Text
View/download PDF

100. Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin.

Author

Andersen, L.P., Holck, Susanne, Kupcinskas, L., Kiudelis, G., Jonaitis, L., Janciauskas, D., Permin, H., Wadström, T., Andersen, L.P., Holck, Susanne, Kupcinskas, L., Kiudelis, G., Jonaitis, L., Janciauskas, D., Permin, H., and Wadström, T.

Abstract

Udgivelsesdato: Jul, The chronic active inflammation caused by Helicobacter pylori is dominated by neutrophils, macrophages, lymphocytes and plasma cells. Several interleukins are involved in the inflammatory process. The aim of this study was to investigate the effect of astaxanthin on gastric inflammation in patients with functional dyspepsia. Forty-four consecutive patients were included, and biopsies were examined for IL-4, IL-6, IL-8, IL-10, interferon-gamma, CD4, CD8, CD14, CD19, CD25 and CD30. Patients were randomized: 21 patients were treated with 40 mg of astaxanthin daily, and 23 patients were treated with a placebo. There was a significant decrease in gastric inflammation in H. pylori-positive patients from both groups. There were no significant changes in the density of H. pylori or in any of the interleukins during or after treatment. There was a significant up-regulation of CD4 and down-regulation of CD8 in patients with H. pylori treated with astaxanthin. Astaxanthin had an effect on the inflammation and on the density of H. pylori in mice in a study where the diet could be standardized without antioxidants (Bennedsen et al., 1999). These dietary conditions are impossible in studies involving humans, and may be due to the minor effect when the host have access to antioxidants in their diet.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results